Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 74 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ofirmev® Clear all
Completed Phase 2 Interventional Results available

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

NCT00576758
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
obinutuzumab (RO5072759), rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
13
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Oct 2, 2026, 5:22 AM EDT
Withdrawn Phase 2 Interventional

Active Temperature Management After Cardiac Surgery and Its Effect on Postoperative Cognitive Dysfunction

NCT03947671
View directory record Official record
Conditions
Cardiac Surgery, Post-operative Cognitive Dysfunction, Fever
Interventions
Rapr Rounds Hyper/Hypothermia Wraps, Acetaminophen
Device · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
20 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 2, 2026, 5:22 AM EDT
Recruiting Phase 4 Interventional

Improving Postoperative Recovery: A Study of Multimodal Perineal Analgesia Protocol (MPAP) After Vaginal Surgery

NCT07401134
View directory record Official record
Conditions
Perineal Injury, Pain Vulva, Perineum; Injury
Interventions
Perineal ice packs, medicated witch-hazel pads, and topical benzocaine spray
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 2, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects

NCT03517930
View directory record Official record
Conditions
Clinical Pharmacology
Interventions
Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG), Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 2, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

NCT04165096
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Boserolimab, MK-4830, diphenhydramine, acetaminophen, MK-0482
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 2, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

NCT06460961
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
MK-6837, Pembrolizumab, Rescue Medications
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Morristown, New Jersey • Portland, Oregon • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 2, 2026, 5:22 AM EDT
Terminated Phase 4 Interventional Results available

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

NCT00166712
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 2, 2026, 5:22 AM EDT
Recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
15
States / cities
Phoenix, Arizona • Burbank, California • Grand Junction, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 2, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults

NCT00573170
View directory record Official record
Conditions
Migraine Disorders, Migraine, Acute
Interventions
TREXIMET®, Butalbital-containing Combination Medications (BCM), placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
107
States / cities
Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2010 · Synced Oct 2, 2026, 5:22 AM EDT
Terminated Phase 4 Interventional Results available

Pharmacokinetics (PK) and Safety Study of XARTEMIS® XR in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain

NCT02508935
View directory record Official record
Conditions
Acute Pain
Interventions
XARTEMIS XR
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
12 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 2, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

NCT04918147
View directory record Official record
Conditions
IgG4 Related Disease, IgG4-RD
Interventions
elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 2, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects

NCT03517943
View directory record Official record
Conditions
Clinical Pharmacology
Interventions
Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG), Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 2, 2026, 5:22 AM EDT
Completed Phase 3 Interventional

Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain

NCT00195728
View directory record Official record
Conditions
Moderate to Severe Chronic, Non-malignant Pain
Interventions
Hydrocodone/Acetaminophen on Extended Release
Drug
Lead sponsor
Abbott
Industry
Eligibility
21 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
76
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2011 · Synced Oct 2, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study

NCT01229449
View directory record Official record
Conditions
Post-operative Pain
Interventions
Ibuprofen/acetaminophen, Ibuprofen/acetaminophen (higher dose), Nurofen Plus®, Panadeine® Extra, Placebo
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
16 Years and older
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 2, 2026, 5:22 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery

NCT07225140
View directory record Official record
Conditions
Post Operative Pain, Acute
Interventions
Combogesic® tablets, Acetaminophen 500mg, Placebo
Drug
Lead sponsor
AFT Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 2, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

NCT00795132
View directory record Official record
Conditions
Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
Interventions
Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 2, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection

NCT05144828
View directory record Official record
Conditions
Pain, Postoperative, Lung Diseases
Interventions
Intercostal Nerve Cryoablation, Patient-controlled analgesia (PCA)
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 2, 2026, 5:22 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair

NCT01500109
View directory record Official record
Conditions
Cleft Palate
Interventions
Oral acetaminophen, Ofirmev®, Opioid only
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
5 Months to 5 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 2, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Bioequivalence of Vycavert (10 mg Hydrocodone Bitartrate/325 mg Acetaminophen) Compared to the Reference Drug Norco

NCT01456520
View directory record Official record
Conditions
Healthy
Interventions
Vycavert, Norco
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Oct 2, 2026, 5:22 AM EDT
Completed Phase 3 Interventional

A Study of Pain Relief in Low Back Pain

NCT00325949
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Extended release hydrocodone and acetaminophen (Vicodin CR), hydrocodone/acetaminophen extended release (Vicodin CR), placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
21 Years to 75 Years
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Hueytown, Alabama • Phoenix, Arizona • Tempe, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 2, 2026, 5:22 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Efficacy Study of IV Ibuprofen vs IV Acetaminophen Post Surgical Extraction

NCT02133326
View directory record Official record
Conditions
Impacted Wisdom Teeth
Interventions
Caldolor, Ofirmev
Drug
Lead sponsor
Tufts University School of Dental Medicine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 2, 2026, 5:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

NCT06780111
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Sacituzumab tirumotecan, Rescue Medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 2, 2026, 5:22 AM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

NCT06788912
View directory record Official record
Conditions
Lung Neoplasm Malignant
Interventions
Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, Pemetrexed, Sacituzumab tirumotecan, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Carboplatin, Pembrolizumab (adjuvant), Paclitaxel, Steroid mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
9
States / cities
Daphne, Alabama • Santa Barbara, California • Lone Tree, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 2, 2026, 5:22 AM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

NCT06043323
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate, Prednisone, Diphenhydramine, Acetaminophen
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 2, 2026, 5:22 AM EDT